*3.13. Pan-JAK Inhibitors*

According to in vitro studies performed on inflammatory cells isolated from asthmatic patients, pan-JAK inhibitors reduced cytokine levels and showed an additive effect on lymphocyte inhibition when combined with ICS [89]. Lung inflammation was improved upon treatment with pan-JAK inhibitors in animal models of airway inflammation [90–92].

A Phase II RCT [27] reported that the pan-JAK inhibitor TD-8236 administered at 150 μg and 1500 μg via DPI did not improve the FEV1 AUC from 3 to 8 h and the maximum percentage decline in FEV1 from 3 to 8 h following inhaled allergen challenge compared to PCB. No data are available for symptoms control [27].
